Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEPEMB in Older Patients With Hodgkin's Lymphoma
NCT00079105Phase 2Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Jan 2004
- Primary completion
- Dec 2010
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label trial of bleomycin, cyclophosphamide, etoposide, mitoxantrone, prednisolone and 2 more in Hodgkin lymphoma (HL) (2 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Disease-free survival at 6 months. Started Jan 2004; status: completed.
02
Drugs
bleomycincyclophosphamideetoposidemitoxantroneprednisolone
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00079105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00079105.